Previous 10 | Next 10 |
Coronavirus Can Quickly Progress to Severe Pneumonia and Even Death Due to Immune Hyperactivity Including Acute Respiratory Distress Syndrome (ARDS); CytoDyn's Trial Focuses on Patients Who Develop Mild-To-Moderate Respiratory Illness After Contracting Coronavirus CytoDyn Negotiating ...
VANCOUVER, Washington, Feb. 28, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced t...
NEW YORK, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published news and CEO Interview updates with the innovative companies which presented at the highly acclaimed “NEXT SUPER STOCK Live!” conference series. The V...
NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published exclusive interviews with top-performing investment experts Dr. Joe Duarte, MD., publisher of “In The Money Options” and Crista Huff, lead analyst at&...
Results from mTNBC and MBC studies continues to be positive with the first patient now at almost five months of treatment showing zero CTC, EMT and CAML. Seven patients have been enrolled to date VANCOUVER, Washington, Feb. 21, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (...
VANCOUVER, Washington, Feb. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced t...
“NEXT SUPER STOCK” Conference presentation videos from: FaceBank Group, INC (OTC: FBNK) CytoDyn Inc. (OTC: CYDY) NexTech AR Solutions Corp. (OTC: NEXCF) Imagination Park Technologies, Inc. (OTC: IPNFF) NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Wall Street Reporter, ...
VANCOUVER, Washington, Feb. 14, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...
VANCOUVER, Washington, Feb. 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...
Investing in penny stocks is often regarded as an effective way for new investors to make money in the market. It’s also a way to leverage small amounts of capital to make large windfalls. I won’t bore you with the details of how to make money with penny stocks. Honestly, it ...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...